EGFR and non-small cell lung carcinoma: Furthermore, osimertinib administration was associated with longer PFS than current standard first‐line treatments for EGFR‐mutated NSCLC.37 Hence, osimertinib might be a more effective standard first‐line treatment for EGFR mutation‐positive NSCLC.